Article Text

other Versions

PDF
Photodynamic therapy for steroid-associated central serous chorioretinopathy
  1. Tae-Gon Lee1,2,
  2. Judy E Kim1
  1. 1The Eye Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
  2. 2Department of Ophthalmology, College of Medicine, Konyang University, Daejeon, Korea
  1. Correspondence to Dr Judy E Kim, The Eye Institute, Medical College of Wisconsin, 925N 87th Street, Milwaukee, WI 53226, USA; judykim{at}mcw.edu

Abstract

Purpose To evaluate the short-term efficacy of photodynamic therapy (PDT) for steroid-associated chronic or recurrent central serous chorioretinopathy (CSC).

Design Interventional case series.

Methods Retrospective review of nine consecutive cases of steroid-associated CSC treated with PDT using half-fluence for fovea involving treatments (n=4) and full-fluence for extrafoveal treatments (n=5). The main outcome measures included anatomical changes measured on optical coherence tomography (OCT) and changes in best-corrected visual acuity (BCVA) after PDT.

Results All eyes had fovea involving serous retinal detachment on OCT, and six (67%) eyes had a history of three or more recurrences. The mean duration of current episode of CSC prior to PDT was 45 months (range: 3–131 months). The mean follow-up after PDT was 8 months (range: 3–18 months). Serous retinal detachment disappeared in all cases following PDT without any complications. One patient had a recurrence and was re-treated. Compared to the mean BCVA of 20/83 (logMAR 0.62) at baseline, the mean BCVA was 20/40 (logMAR 0.33) at 3 months (p=0.018), and 20/47 (logMAR 0.37) at last follow up (p=0.075). Visual acuity improved by at least two lines in three (33%) eyes.

Conclusions Despite chronicity and recurrences seen in steroid-associated CSC, serous retinal detachment resolved in all cases, and a modest improvement in visual acuity was observed following PDT, at least for the short term. Given the difficulty of managing these cases, PDT as applied in this study may be an effective treatment.

  • Central serous chorioretinopathy
  • photodynamic therapy
  • steroid
  • reduced-fluence
  • choroid
  • retina, macula
  • treatment other

Statistics from Altmetric.com

Footnotes

  • Funding Unrestricted funding from Research to Prevent Blindness, New York.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by the IRB of Medical College of Wisconsin.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.